Herr Megan M, Fries Kristin M, Upton L George, Edsberg Laura E
Natural Sciences Department, Daemen College, Amherst, NY, USA.
J Oral Maxillofac Surg. 2011 Jan;69(1):41-7. doi: 10.1016/j.joms.2010.05.013.
The purpose of this study was to identify protein markers present in subjects with temporomandibular joint disorders (TMDs) and clicking compared with the levels in controls.
This was a pilot case-control study, and we report the preliminary results. Samples of joint aspirate collected from patients with TMDs and controls who had undergone surgery for a problem other than TMDs were analyzed using isobaric tags for relative and absolute quantitation (iTRAQ) and biotin-labeled-based protein arrays. The data obtained from these techniques were used to identify the proteins of interest, which were then quantitated using enzyme-linked immunosorbent assay (ELISA). The patient samples studied included joint aspirate collected clinically from the controls and patients and included samples from both the right and the left sides of each patient with a TMD.
The 8 TMJ aspirate samples from 6 subjects included 5 aspirate samples from 4 patients and 3 from 2 controls. The greatest standardized protein concentration of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 (EG-VEGF/PK1) and D6 was found in both joints of the controls compared with the levels from the joints of the patients. With 1 exception, the standardized protein concentration was significantly lower in the patients than in the controls. The lower levels of EG-VEGF/PK1 and D6 in the patients compared with the controls suggest that these cytokines might be possible biomarkers for TMDs.
In the present pilot study, greater levels of EG-VEGF/PK1 and D6 were found in the controls than in the patients with TMDs. Proteomic analysis of the proteins present in the diseased joints compared with those in the controls might help to identify proteins present when pain or degeneration of the joint occurs. The proteomic information might be useful in the development of future therapies.
本研究的目的是确定颞下颌关节紊乱病（TMD）患者和有弹响症状的患者体内存在的蛋白质标志物，并与对照组的水平进行比较。
这是一项试点病例对照研究，我们报告初步结果。使用相对和绝对定量等压标签（iTRAQ）和基于生物素标记的蛋白质阵列，对从患有TMD的患者以及因TMD以外的问题接受手术的对照组患者采集的关节抽吸物样本进行分析。从这些技术获得的数据用于鉴定感兴趣的蛋白质，然后使用酶联免疫吸附测定（ELISA）对其进行定量。所研究的患者样本包括从对照组和患者临床采集的关节抽吸物，并且包括每个患有TMD的患者左右两侧的样本。
来自6名受试者的8个颞下颌关节抽吸物样本包括来自4名患者的5个抽吸物样本和来自2名对照组的3个样本。与患者关节中的水平相比，在对照组的两个关节中发现内分泌腺衍生的血管内皮生长因子/促动力蛋白-1（EG-VEGF/PK1）和D6的标准化蛋白质浓度最高。除1个例外，患者的标准化蛋白质浓度显著低于对照组。与对照组相比，患者体内EG-VEGF/PK1和D6水平较低表明这些细胞因子可能是TMD的生物标志物。
在本试点研究中，发现对照组中EG-VEGF/PK1和D6的水平高于患有TMD的患者。对患病关节中存在的蛋白质与对照组中的蛋白质进行蛋白质组学分析，可能有助于识别关节出现疼痛或退变时存在的蛋白质。蛋白质组学信息可能对未来治疗方法的开发有用。
